Latest Ratios: P/E Ratio 27.1x · EV/EBITDA 19.9x · ROE -19.2%. (1995–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $5.1B | $3.4B | $2.5B | $2.8B | $3.0B | $4.4B | $3.2B | $3.6B | $4.4B | $3.9B | $2.2B |
| Enterprise Value | $4.9B | $3.2B | $2.8B | $3.2B | $3.3B | $4.5B | $3.7B | $4.0B | $4.6B | $3.9B | $2.3B |
| P/E Ratio → | 27.06 | — | 39.92 | 161.69 | — | — | — | — | — | — | — |
| P/S Ratio | 3.37 | 2.42 | 2.02 | 2.43 | 2.91 | 4.28 | 3.44 | 3.36 | 4.01 | 3.83 | 1.81 |
| P/B Ratio | 4.20 | 2.79 | 1.91 | 2.20 | 2.46 | 3.42 | 2.90 | 2.64 | 2.95 | 2.14 | 1.29 |
| P/FCF | 39.38 | 19.36 | 18.59 | 70.24 | 68.47 | 57.44 | — | — | 53.77 | 67.76 | 41.49 |
| P/OCF | 19.97 | 13.19 | 13.81 | 37.44 | 42.51 | 43.17 | — | — | 36.81 | 42.45 | 24.38 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.30 | 2.21 | 2.76 | 3.27 | 4.35 | 3.93 | 3.67 | 4.12 | 3.88 | 1.88 |
| EV / EBITDA | 19.85 | 13.22 | 15.40 | — | — | 67.04 | — | — | — | 23.68 | 39.51 |
| EV / EBIT | 24.65 | — | 18.33 | — | — | — | — | 82.09 | — | 30.47 | 63.70 |
| EV / FCF | — | 18.42 | 20.42 | 79.60 | 76.90 | 58.46 | — | — | 55.24 | 68.68 | 43.06 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 67.7% | 67.7% | 69.5% | 66.9% | 69.2% | 68.2% | 63.7% | 66.8% | 66.4% | 64.4% | 58.0% |
| Operating Margin | 14.4% | 14.4% | 10.3% | -5.9% | -7.5% | -0.1% | -29.3% | -15.8% | -22.4% | 9.5% | -2.3% |
| Net Profit Margin | -17.5% | -17.5% | 5.0% | 1.5% | -8.4% | -13.1% | -37.3% | -14.5% | -17.1% | -2.5% | -5.2% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -19.2% | -19.2% | 4.9% | 1.4% | -6.9% | -11.3% | -28.0% | -10.9% | -11.4% | -1.4% | -3.6% |
| ROA | -9.5% | -9.5% | 2.6% | 0.7% | -3.8% | -5.9% | -14.5% | -6.4% | -7.5% | -1.0% | -2.6% |
| ROIC | 11.5% | 11.5% | 6.0% | -3.2% | -3.9% | -0.0% | -12.5% | -7.7% | -10.7% | 3.9% | -1.1% |
| ROCE | 10.2% | 10.2% | 6.1% | -3.3% | -4.4% | -0.0% | -13.7% | -8.7% | -12.0% | 4.6% | -1.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.39 | 0.39 | 0.51 | 0.50 | 0.48 | 0.22 | 0.64 | 0.29 | 0.11 | 0.08 | 0.07 |
| Debt / EBITDA | 1.96 | 1.96 | 3.76 | — | — | 4.27 | — | — | — | 0.88 | 2.13 |
| Net Debt / Equity | — | -0.14 | 0.19 | 0.29 | 0.30 | 0.06 | 0.41 | 0.24 | 0.08 | 0.03 | 0.05 |
| Net Debt / EBITDA | -0.67 | -0.67 | 1.38 | — | — | 1.17 | — | — | — | 0.32 | 1.44 |
| Debt / FCF | — | -0.94 | 1.82 | 9.36 | 8.44 | 1.02 | — | — | 1.47 | 0.92 | 1.57 |
| Interest Coverage | -3.48 | -3.48 | 2.40 | -0.38 | -0.56 | -1.48 | -1.49 | 3.21 | -24.19 | 16.54 | 3.37 |
Net cash position: cash ($636M) exceeds total debt ($473M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.36 | 1.36 | 2.87 | 2.95 | 2.98 | 0.97 | 2.29 | 1.07 | 1.07 | 2.14 | 1.96 |
| Quick Ratio | 1.16 | 1.16 | 2.50 | 2.51 | 2.54 | 0.82 | 1.92 | 0.75 | 0.76 | 1.79 | 1.38 |
| Cash Ratio | 0.79 | 0.79 | 1.09 | 0.80 | 0.72 | 0.30 | 0.82 | 0.12 | 0.10 | 0.23 | 0.13 |
| Asset Turnover | — | 0.53 | 0.50 | 0.47 | 0.45 | 0.47 | 0.39 | 0.45 | 0.43 | 0.40 | 0.52 |
| Inventory Turnover | 2.72 | 2.72 | 2.59 | 2.59 | 2.43 | 3.11 | 2.94 | 2.20 | 2.43 | 2.50 | 2.78 |
| Days Sales Outstanding | — | 56.80 | 65.14 | 68.05 | 76.74 | 78.61 | 72.34 | 86.98 | 84.44 | 103.20 | 64.12 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 3.7% | — | 2.5% | 0.6% | — | — | — | — | — | — | — |
| FCF Yield | 2.5% | 5.2% | 5.4% | 1.4% | 1.5% | 1.7% | — | — | 1.9% | 1.5% | 2.4% |
| Buyback Yield | 0.1% | 0.1% | 0.3% | 0.3% | 0.3% | 0.3% | 0.2% | 0.2% | 1.4% | 0.1% | 2.5% |
| Total Shareholder Yield | 0.1% | 0.1% | 0.3% | 0.3% | 0.3% | 0.3% | 0.2% | 0.2% | 1.4% | 0.1% | 2.5% |
| Shares Outstanding | — | $55M | $55M | $54M | $54M | $51M | $49M | $48M | $48M | $49M | $49M |
Includes 30+ ratios · 30 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying LIVN stock.
LivaNova PLC's current P/E ratio is 27.1x. The historical average is 100.8x.
LivaNova PLC's current EV/EBITDA is 19.9x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 31.8x.
LivaNova PLC's return on equity (ROE) is -19.2%. The historical average is -18.7%.
Based on historical data, LivaNova PLC is trading at a P/E of 27.1x. Compare with industry peers and growth rates for a complete picture.
LivaNova PLC has 67.7% gross margin and 14.4% operating margin. Operating margin between 10-20% is typical for established companies.
LivaNova PLC's Debt/EBITDA ratio is 2.0x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.
Key Metrics
Top Statement Risk
Non-operating charges eroding earnings
Metrics are mathematically derived from official filings.
Negative Trailing Earnings Distort Multiples
Based on reported figures, LIVN trades at a trailing P/E of -20.22 but a forward P/E of 20.66, and the swing suggests the market is pricing recovery rather than current earnings power.
The gap between a negative trailing P/E and a forward P/E near 21x indicates that trailing multiples are largely uninformative given the large non-operating losses in recent quarters. The forward EV/EBITDA of 11.32 versus a trailing 19.81 implies that consensus expects EBITDA to expand meaningfully, which investors should test against the operating margin compression seen from 15.4% to 7.2%. Relative to peers, the P/B of 4.09 appears elevated given a negative ROE of -19.2%, suggesting the price relies on the durability of the installed VNS and Essenz base.
Operating Margin Erosion Versus Net Losses
Reported operating margin fell from 15.4% in 2025Q2 to 7.2% in 2026Q3, while the trailing net margin of -17.5% indicates non-operating items are absorbing most of the operating profit.
Gross margins have held in a tight 66% to 71% band, so the compression is occurring below gross profit, pointing to rising operating expense intensity rather than pricing or input cost pressure. The divergence between a positive operating margin and a negative trailing net margin suggests interest, impairments, or litigation charges are doing the damage, which warrants reconciliation against GAAP filings. Operating margin, not net margin, is the better gauge of underlying earnings power, though it should be adjusted for recurring restructuring costs before being treated as sustainable.
Deleveraging Progress Against Thin Coverage
Debt-to-equity fell from 0.55 in 2024Q2 to 0.25 in 2026Q3, and interest coverage of 6.85x in the latest quarter suggests debt service is comfortable on current figures.
The reduction in D/E and D/EBITDA from 13.95 to 6.35 indicates the company is materially less levered than two years ago, though interest coverage has been volatile, swinging from 2.40x to 13.69x on reported quarterly figures. Coverage ratios are sensitive to quarterly EBITDA timing, so the trend warrants monitoring rather than being taken at face value. The deleveraging appears to have been funded partly by cash balances rather than sustained profitability, which suggests the improvement may be less durable than the headline ratio implies.
Current Ratio Normalizing From Elevated Levels
According to reported figures, the current ratio declined from 3.45 in 2024Q2 to 1.46 in 2026Q3, and the quick ratio of 1.22 still indicates a reasonable cushion without reliance on inventory.
The decline in current ratio reflects a shift in working capital composition rather than a deterioration in ability to meet near-term obligations, since quick ratio remains above 1.0. The cash conversion cycle has moved from 131 days to 116 days, driven by a lengthening DPO and a shorter DSO, which suggests improved receivables management. Under severe stress, the position would likely remain adequate given the quick ratio, though the dependence on cash balances for liquidity warrants investor attention.
Asset Turnover Masks Reinvestment Pressure
The asset turnover ratio of 0.15 and rising capital expenditure at roughly 7.8% of revenue suggest the company's capital base is growing faster than its revenue generation.
A low asset turnover of 0.15 is typical of a medical device business with significant intangible and fixed asset intensity, so the metric should be read against peers rather than in isolation. The step-up in capex from 3.2% to 7.8% of revenue may reflect platform investment that could support future margins, but it also raises the question of whether returns on invested capital, currently around 1.8%, will recover. The most commonly misapplied metric here is ROE, which is distorted by the accumulated deficit and recent equity rebuilding, and investors should instead anchor on ROIC and operating margin trends.